Reaction

Chronic Graft Versus Host Disease reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,592 reports · 102 co-occurring drugs

As of the last recalculation, Chronic Graft Versus Host Disease appears in 3,592 FAERS reports alongside 102 co-occurring drug terms. The strongest observed disproportionality signal is BUSULFAN (PRR 289.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Busulfan	645	289.3	301.7
Fludarabine Phosphate	938	186.7	191.3
Thiotepa	265	173.5	178.5
Anti-Thymocyte Globulin (Rabbit)	170	128.1	130.9
Sirolimus	216	98.8	100.4
Melphalan Hydrochloride	365	93.8	95.2
Cyclosporine	1,203	93.7	94.7
Melphalan	304	84.5	85.6
Mycophenolate Mofetil	1,168	73.4	74.0
Mycophenolate Mofetil Hydrochloride	1,168	73.2	73.9
Tacrolimus	1,201	66.2	66.8
Tacrolimus Ointment 0.1%	965	61.0	61.5
Tacrolimus Extended-Release Capsules	965	60.9	61.3
Imatinib	165	56.8	57.3
Cyclophosphamide Injection, Solution	1,056	48.5	48.8
Cyclophosphamide	1,056	48.5	48.8
Cyclophosphamide For Injection	1,056	48.5	48.8
Posaconazole Delayed-Release	86	46.5	46.8
Blinatumomab	81	46.0	46.4
Ganciclovir	76	43.9	44.3
Ganciclovir Sodium	77	43.1	43.4
Alemtuzumab	131	40.7	41.0
Posaconazole	101	37.0	37.3
Micafungin Sodium	48	33.2	33.4
Mesna Injection	46	32.7	32.8
Mesna	46	32.1	32.2
Ruxolitinib	331	29.4	29.5
Methotrexate	1,168	23.4	23.4
Methotrexate Sodium	1,227	21.7	21.8
Basiliximab	43	21.4	21.5
Filgrastim	133	21.2	21.3
Cytarabine	196	19.9	20.0
Amphotericin B	39	18.2	18.3
Mycophenilic Acid	64	18.2	18.3
Ursosiol	57	17.2	17.3
Voriconazole	82	16.0	16.0
Ursodiol	58	15.7	15.7
Voriconazole Injection	57	15.4	15.5
Methylprednisolone	329	15.1	15.1
Everolimus Tablets	43	15.0	15.1
Mycophenolic Acid	77	14.2	14.3
Azacitidine For	44	14.2	14.2
Itraconazole	27	13.5	13.5
Etoposide	162	13.3	13.4
Prednisolone	366	13.0	13.0
Prednisolone Oral	366	13.0	13.0
Prednisolone Oral Solution	366	13.0	13.0
Azacitidine	62	12.3	12.3
Valganciclovir Hydrochloride Powder,	24	11.5	11.5
Fluconazole	133	11.4	11.4
Acyclovir	206	11.0	11.0
Hydrocortisone Sodium Succinate	17	10.5	10.5
Valganciclovir	32	9.9	9.9
Valganciclovir Hydrochloride	32	9.9	9.9
Ibrutinib	129	9.6	9.6
Phenytoin	34	9.5	9.5
Granisetron Hydrochloride	17	9.5	9.5
Rituximab	304	9.0	9.0
Polatuzumab Vedotin	13	7.7	7.8
Dalteparin Sodium	14	7.7	7.7
Eltrombopag Olamine	30	7.6	7.6
Atovaquone	10	7.2	7.2
Sulfamethoxazole And Trimethoprim	96	6.7	6.8
Imatinib Mesylate	30	6.3	6.3
Sorafenib	22	6.2	6.2
Hydroxyurea	22	6.1	6.1
Methylprednisolone Sodium Succinate	47	5.9	5.9
Bortezomib	85	5.6	5.6
Ifosfamide	20	5.4	5.4
Daspone	9	5.4	5.4
Dapsone Gel, 5%	9	5.4	5.4
Azithromycin	36	5.2	5.2
Azathioprine	78	5.2	5.2
Azithromycin Monohydrate	36	5.0	5.1
Montelukast	71	5.0	5.0
Everolimus	43	4.9	4.9
Valacyclovir	35	4.9	4.9
Dapsone	9	4.9	4.9
Cladribine	8	4.8	4.8
Dasatinib	28	4.4	4.4
Cefepime Hydrochloride	12	4.3	4.3
Valacyclovir Hydrochloride	50	4.2	4.2
Prednisolone Acetate	7	3.9	3.9
Obinutuzumab	11	3.9	3.9
Thalidomide	24	3.8	3.8
Heparin Sodium	9	3.8	3.8
Levofloxacin	39	3.8	3.8
Levofloxacin In 5% Dextrose	39	3.8	3.8
Carboxymethylcellulose Sodium	6	3.7	3.7
Nilotinib	18	3.5	3.6
Cisplatin	44	3.3	3.3
Gemcitabine	21	3.1	3.1
Dexamethasone 1.5 Mg	146	3.0	3.0
Dexamethasone	147	3.0	3.0
Doxorubicin	44	2.9	2.9
Brentuximab Vedotin	5	2.8	2.8
Bendamustine Hcl	7	2.6	2.6
Bendamustine Hydrochloride	5	2.4	2.4
Gemcitabine Hydrochloride	22	2.4	2.4
Venetoclax	25	2.4	2.4
Romiplostim	5	1.9	1.9
Daratumumab	11	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.